"La Clinique CHC MontLégia est un hôpital flambant neuf construit sur le site de Patience et Beaujonc à l’entrée ouest de Liège. Elle a été mise en service en mars 2020, et regroupe l’activité des anciennes cliniques Saint-Joseph, Espérance et Saint-Vincent. Notre nouvel hôpital propose une offre de soins complète (hospitalisation, consultations, examens médicaux) et dispose d’un équipement de dernière génération. La lumière naturelle, le confort des chambres avec une belle vue sur la ville, l’ergonomie du bâtiment, l’accessibilité constituent quelques-uns des atouts de la Clinique CHC MontLégia."

During the past decade, CHC Liege conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHC Liege" #1 sponsor was "Aravive, Inc." with 1 trials, followed by "Benvenue Medical, Inc." with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Chiesi SA/NV" with 1 trials sponsored and "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHC Liege" #1 collaborator was "Bicetre Hospital" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator, "GOG Foundation" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator and "Hospices Civils de Lyon" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "CHC Liege" are "Arthritis, Juvenile Rheumatoid" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials), "Cardiovascular Disease" (1 trials), "Cardiovascular Diseases" (1 trials) and "Degenerative Disc Disease (DDD)" (1 trials). Many other conditions were trialed in "CHC Liege" in a lesser frequency.

Most popular intervention types in "CHC Liege" are "Drug" (5 trials), "Other" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Batiraxcept" (1 trials), "Cysteamine Bitartrate" (1 trials), "Filgotinib" (1 trials) and "IMNOVID" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHC Liege" are 8 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CHC Liege". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 4 completed trials in CHC Liege, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CHC Liege, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".